Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nuvectis Pharma, Inc. - Common Stock
(NQ:
NVCT
)
7.600
+0.840 (+12.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nuvectis Pharma, Inc. - Common Stock
< Previous
1
2
Next >
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 07, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
September 16, 2024
From
PESG Research
Via
Business Wire
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT)
August 15, 2024
Via
AB Newswire
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market
July 18, 2024
Via
AB Newswire
Precision Medicine M&A is Transforming the Future of the Biotech Industry
June 17, 2024
Via
AB Newswire
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
May 16, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
April 08, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
March 19, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Present at the 36th Annual Roth Conference
March 15, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
March 14, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
February 09, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
February 09, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
December 18, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
October 24, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
September 25, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
September 21, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
September 12, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
September 06, 2023
Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
September 01, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
August 17, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
June 20, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
May 15, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
April 27, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
April 27, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
April 18, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
April 10, 2023
Phase 1b study builds on highly consistent preclinical and Phase 1a data
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
March 17, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
March 10, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.